Session 3: October 26, 2021 9:00 AM CDT

A Microsatellite Instability (MSI) Series

MSI has rapidly advanced as an important pan tumor biomarker associated with response to immune checkpoint inhibitors and the drive towards universal tumor testing.

Join Session 3 to learn more about MSI from two esteemed speakers who will present on the following topics:

Performance of the industry's first and only PCR-based diagnostic kit for MSI characterization (FDA-cleared)
The most current clinical practice guidelines for MSI testing
MSI detection using PCR followed by capillary electrophoresis (CE) analysis
The clinical utility of the MSI biomarker for Lynch syndrome screening and immunotherapy treatment
Compare techniques used to measure MSI to current gold-standard methods

In addition to the presentations, you will have the opportunity to:

Peruse our booth to view instrument demonstrations from our sample-to-answer workflow for MSI analysis
Connect with Promega Clinical Consultants and Medical Affairs representatives
View the presentations from Session 1 and 2 where our speakers discussed the history, testing strategies and current trends for MSI testing and why MSI status should be a universal testing approach

Speakers

Kathryn Oostdik

Sr. Global Product Manager, Clinical Diagnostics, Promega Corporation
BIOGRAPHY
Dr. Emily Teslow, Ph.D.

Medical Science Liaison, Medical Affairs Dept, Promega Corporation
BIOGRAPHY
Dr. Ryan Nguyen, DO

Chief Hematology and Oncology Fellow, University of Illinois at Chicago
BIOGRAPHY
Dr. Samantha Lewis, Ph.D.

Clinical Development Specialist, Promega Corporation
BIOGRAPHY
Dr. Pamela Ward, Ph.D.

Associate Professor of Clinical Pathology, Scientific Director, USC Clinical Laboratories, Molecular Pathology
BIOGRAPHY
Jeff Bacher, PhD

Senior Research Scientist, Promega Corporation, Adjunct Professor, UW-Madison, Dept. of Medicine
BIOGRAPHY
James Eshleman, MD, PhD

Professor of Pathology and Oncology, Associate Director, Molecular Diagnostics Laboratory, Johns Hopkins University School of Medicine
BIOGRAPHY
Heather Hampel, MS

LGC Associate Director, Division of Human Genetics, Associate Director, Biospecimen Research Professor, Internal Medicine, Licensed Genetic Counselor, The Ohio State University Cancer Center
BIOGRAPHY
Gerard Blobe, MD, PhD

Professor of Medicine, Pharmacology and Cancer Biology at Duke University School of Medicine, Associate Director of Training and Education for the Duke Cancer Institute
BIOGRAPHY

Show Resources

You May Also Like

DEC 07, 2021 12:30 PM EST

NCATS at 10: Improving Health for All Through Translational Science

Date: December 7, 2021 Time: 12:30-5:00 p.m. ET #NCATS10...

APR 19, 2022 6:00 AM PDT

Genetics Virtual Week 2022

LabRoots is excited to announce our 10th Annual Genetics Virtual Week held on April 19-21, 2022! Genetics Virtual Week 2022 will offer a multi-day content-rich program combining stellar expe...

JAN 25, 2022 1:00 AM PST

Lab Compliance Connect

Europe - 10:00 AM Central European Time United Kingdom - 10:00 AM British Summer Time North America - 10:00 AM Central Standard Time Lab Compliance Connect – The world’s leading...

SEP 06, 2022 6:00 AM PDT

Microbiology Virtual Week 2022

LabRoots is excited to bring academia and industry, research experts, virologists, microbiologists, healthcare professionals, and leading biomedical scientists under one roof at our 8th Annu...

NOV 10, 2021 6:00 AM PST

C.E. CREDITS

NOV 10, 2021 6:00 AM PST

Clinical Diagnostics & Research 2021

Twelve years ago Labroots launched a new system of learning for a global scientific audience. Now, the 2021 Clinical Diagnostics and Research Virtual Event...

NOV 09, 2022 6:00 AM PST

Clinical Diagnostics & Research 2022

Thirteen years ago Labroots launched a new system of learning for a global scientific audience. Now, the 2022 Clinical Diagnostics and Research Virtual Event will again bring together clinic...

Speakers

Oct 26, 2021 11:00 AM CDT

Current Gold-Standards for MSI Testing and the Clinical Relevance of the MSI-H Biomarker
Dr. Emily Teslow, Ph.D.

Medical Science Liaison, Medical Affairs Dept, Promega Corporation
BIOGRAPHY
Dr. Emily Teslow will discuss MSI testing gold standards and compare the different methods that are currently being used for microsatellite instability (MSI) testing for mismatch repair deficient (dMMR) tumors. Then she will discuss the clinical relevance of the MSI-H biomarker focusing on the pathological and epidemiological characteristics of MSI-H/dMMR tumors, and the role of MSI testing in Lynch syndrome screening, colorectal cancer patient prognosis, and immunotherapy treatment.

Learning objectives

Compare techniques used to measure microsatellite instability to current gold-standard methods

Discuss the clinical utility of the MSI biomarker for Lynch syndrome screening and immunotherapy treatment

Review the most current clinical practice guidelines for MSI testing
SEE ABSTRACT HIDE ABSTRACT | Continuing Education: P.A.C.E. CE | Florida CE
Oct 26, 2021 12:00 PM CDT

Performance of the OncoMate™ MSI Dx Analysis System
Kathryn Oostdik

Sr. Global Product Manager, Clinical Diagnostics, Promega Corporation
BIOGRAPHY
Screening cancer patients for microsatellite instability (MSI) can provide pathologists, oncologists, and patients with information that characterizes tumors to help guide care and make more informed decisions. With the growing demand for MSI testing and recognition of its value as a biomarker, the need for a reliable and cost-effective MSI test has increased in recent years. In this presentation, Ms. Oostdik will discuss the new OncoMate™ MSI Dx Analysis System, a FDA-cleared PCR-based MSI kit. The system uses the most sensitive panel of markers for MSI status detection, as included in multiple clinical guidelines. Topics in this presentation will include assay design, intended use, and clinical performance of OncoMate™ MSI Dx. The automated analysis software included in the system will also be discussed.

Learning objectives

Present the relationship between mismatch repair deficiency and microsatellite instability

Describe microsatellite instability detection using PCR followed by capillary electrophoresis (CE) analysis

Describe the use of microsatellite instability status for Lynch Syndrome screening in colorectal cancer (CRC)

Summarize the performance of the OncoMate™ MSI Dx Analysis System as an aid to identify colorectal cancer (CRC) patients who may benefit from further testing to screen for Lynch syndrome, the most common form of hereditary CRC
SEE ABSTRACT HIDE ABSTRACT

JUN 29, 2021 11:15 AM CDT

Tracking MSI status in liquid biopsies from MSI-H colorectal cancer subjects on immunotherapy

Dr. Pamela Ward, Ph.D.

Associate Professor of Clinical Pathology, Scientific Director, USC Clinical Laboratories, Molecular Pathology
BIOGRAPHY

Microsatellite instability, a hallmark of mismatch repair-deficient cancers, is typically associated with good response to immunotherapy. We sought to evaluate the merit of using liquid biopsies to detect microsatellite instability in subjects with stage IV colorectal adenocarcinoma. DNA extracted from ccfDNA and buffy coats was used as source of tumor DNA and germline DNA respectively. Aberrant microsatellite allele sizes were readily detectable in 7 of 8 cases where baseline or second treatment cycles liquid biopsy samples were available from subjects with mismatch repair-deficient cancers. The only sample that tested negative was from a subject whose primary tumor showed MSI heterogeneity and was unresponsive to immunotherapy. MSI-H status of longitudinal liquid biopsy samples was found to correlate with response to immunotherapy. This limited study suggests testing for microsatellite instability in liquid biopsies from subjects with advanced colorectal cancers may help in predicting response to immunotherapy.

SEE ABSTRACT HIDE ABSTRACT
JUN 29, 2021 10:40 AM CDT

Development of a Microsatellite Instability Assay Utilizing Novel Long Repeats
Dr. Samantha Lewis, Ph.D.

Clinical Development Specialist, Promega Corporation
BIOGRAPHY
Dr. Samantha Lewis will discuss the value of MSI as a biomarker and techniques to measure microsatellite instability. She will then describe the development of a new PCR assay to detect MSI in solid tumors utilizing a new 8-marker panel that includes both gold standard markers and novel long mononucleotide repeats for a research-based approach to maximize sensitivity. Dr. Lewis will demonstrate the utility of this novel panel by showcasing studies using difficult and degraded samples (ccfDNA and FFPE).

Learning Objectives:

Demonstrate how mismatch repair deficiency causes microsatellite instability

Recognize techniques to measure microsatellite instability

Discuss why long mononucleotide markers may offer a different perspective on MSI
SEE ABSTRACT HIDE ABSTRACT | Continuing Education: P.A.C.E. CE | Florida CE
JUN 29, 2021 10:00 AM CDT

Colorectal Cancer Disparities and the Role of MSI Testing and Implementation
Dr. Ryan Nguyen, DO

Chief Hematology and Oncology Fellow, University of Illinois at Chicago
BIOGRAPHY
Dr. Nguyen will discuss the disparities in colorectal cancer outcomes and how precision medicine has the potential to exacerbate health disparities due to differences in access and implementation.

Learning Objectives:

Identify disparities in colorectal cancer outcomes.

Describe the role of MSI testing and implementation in colorectal cancer outcomes.

Formulate strategies on how to mitigate disparities in MSI testing and implementation in colorectal cancer.
SEE ABSTRACT HIDE ABSTRACT | Continuing Education: P.A.C.E. CE | Florida CE
Clinical Testing and Implication of MSI Testing in GI Cancers

Gerard Blobe, MD, PhD

Professor of Medicine, Pharmacology and Cancer Biology at Duke University School of Medicine, Associate Director of Training and Education for the Duke Cancer Institute
BIOGRAPHY

Dr. Blobe will be discussing the use of a universal MSI testing approach to identify candidates for immunotherapeutic treatment of Colorectal and other GI Cancers, including Biliary Tract, Esophageal, Anal, and Gastric Cancers.

SEE ABSTRACT HIDE ABSTRACT
Universal Tumor Screening for Lynch Syndrome: Past, Present and Future

Heather Hampel, MS

LGC Associate Director, Division of Human Genetics, Associate Director, Biospecimen Research Professor, Internal Medicine, Licensed Genetic Counselor, The Ohio State University Cancer Center
BIOGRAPHY

Ms. Hampel will be discussing the growing importance and implications of universal MSI/dMMR screening for Lynch Syndrome-associated cancers to aid in identifying patients and their family members who may be affected.

Learning Objectives:

• State the number of individuals in the U.S. with Lynch Syndrome
• Describe the importance of universal screening for identifying individuals with Lynch Syndrome

SEE ABSTRACT HIDE ABSTRACT | Continuing Education: P.A.C.E. CE | Florida CE
MSI Predicts Immunotherapeutic Response

James Eshleman, MD, PhD

Professor of Pathology and Oncology, Associate Director, Molecular Diagnostics Laboratory, Johns Hopkins University School of Medicine
BIOGRAPHY

Dr. Eshleman will be discussing how MSI provides a functional readout of mismatch repair status, the implications of mismatch repair deficiency in cancer cells, and how elevated mutation rate associated with MSI-H tumor cells drive the production of neoantigens thought to contribute to immunotherapeutic response.

Learning Objectives:

• Recall implications of mismatch repair deficiency in solid tumors
• Define Key advantages of Long Mononucleotide Repeats (LMRs) in detecting microsatellite instability

SEE ABSTRACT HIDE ABSTRACT | Continuing Education: P.A.C.E. CE | Florida CE
Past, Present and Future: Advances in MSI Testing

Jeff Bacher, PhD

Senior Research Scientist, Promega Corporation, Adjunct Professor, UW-Madison, Dept. of Medicine
BIOGRAPHY

Dr. Bacher will be discussing the history and evolution of MSI, the differences between popular testing methods, and what the future holds for this powerful biomarker.

Learning Objectives:

• Explain what a microsatellite is, how errors in microsatellites are repaired and indicate how MSI testing is done
• Compare and contrast the characteristics of laboratory assays used to test for microsatellite instability in solid tumors

SEE ABSTRACT HIDE ABSTRACT | Continuing Education: P.A.C.E. CE | Florida CE

Agenda

Download Agenda Here

On Demand Sessions

Colorectal Cancer Disparities and the Role of MSI Testing and Implementation

Dr. Ryan Nguyen, DO

Chief Hematology and Oncology Fellow, University of Illinois at Chicago
BIOGRAPHY

Dr. Nguyen will discuss the disparities in colorectal cancer outcomes and how precision medicine has the potential to exacerbate health disparities due to differences in access and implementation.

SEE ABSTRACT HIDE ABSTRACT | Continuing Education: Florida CE | P.A.C.E. CE
Development of a Microsatellite Instability Assay Utilizing Novel Long Repeats

Dr. Samantha Lewis, Ph.D.

Clinical Development Specialist, Promega Corporation
BIOGRAPHY

Dr. Samantha Lewis will discuss the value of MSI as a biomarker and techniques to measure microsatellite instability. She will then describe the development of a new PCR assay to detect MSI in solid tumors utilizing a new 8-marker panel that includes both gold standard markers and novel long mononucleotide repeats for a research-based approach to maximize sensitivity. Dr. Lewis will demonstrate the utility of this novel panel by showcasing studies using difficult and degraded samples (ccfDNA and FFPE).

SEE ABSTRACT HIDE ABSTRACT | Continuing Education: Florida CE | P.A.C.E. CE
Tracking MSI status in liquid biopsies from MSI-H colorectal cancer subjects on immunotherapy

Dr. Pamela Ward, Ph.D.

Associate Professor of Clinical Pathology, Scientific Director, USC Clinical Laboratories, Molecular Pathology
BIOGRAPHY

Microsatellite instability, a hallmark of mismatch repair-deficient cancers, is typically associated with good response to immunotherapy. We sought to evaluate the merit of using liquid biopsies to detect microsatellite instability in subjects with stage IV colorectal adenocarcinoma. DNA extracted from ccfDNA and buffy coats was used as source of tumor DNA and germline DNA respectively. Aberrant microsatellite allele sizes were readily detectable in 7 of 8 cases where baseline or second treatment cycles liquid biopsy samples were available from subjects with mismatch repair-deficient cancers. The only sample that tested negative was from a subject whose primary tumor showed MSI heterogeneity and was unresponsive to immunotherapy. MSI-H status of longitudinal liquid biopsy samples was found to correlate with response to immunotherapy. This limited study suggests testing for microsatellite instability in liquid biopsies from subjects with advanced colorectal cancers may help in predicting response to immunotherapy.

SEE ABSTRACT HIDE ABSTRACT
Clinical Testing and Implication of MSI Testing in GI Cancers

Gerard Blobe, MD, PhD

Professor of Medicine, Pharmacology and Cancer Biology at Duke University School of Medicine, Associate Director of Training and Education for the Duke Cancer Institute
BIOGRAPHY

Dr. Blobe will be discussing the use of a universal MSI testing approach to identify candidates for immunotherapeutic treatment of Colorectal and other GI Cancers, including Biliary Tract, Esophageal, Anal, and Gastric Cancers.

SEE ABSTRACT HIDE ABSTRACT
Universal Tumor Screening for Lynch Syndrome: Past, Present and Future

Heather Hampel, MS

LGC Associate Director, Division of Human Genetics, Associate Director, Biospecimen Research Professor, Internal Medicine, Licensed Genetic Counselor, The Ohio State University Cancer Center
BIOGRAPHY

Ms. Hampel will be discussing the growing importance and implications of universal MSI/dMMR screening for Lynch Syndrome-associated cancers to aid in identifying patients and their family members who may be affected.

Learning Objectives:

• State the number of individuals in the U.S. with Lynch Syndrome
• Describe the importance of universal screening for identifying individuals with Lynch Syndrome

SEE ABSTRACT HIDE ABSTRACT | Continuing Education: Florida CE | P.A.C.E. CE
MSI Predicts Immunotherapeutic Response

James Eshleman, MD, PhD

Professor of Pathology and Oncology, Associate Director, Molecular Diagnostics Laboratory, Johns Hopkins University School of Medicine
BIOGRAPHY

Dr. Eshleman will be discussing how MSI provides a functional readout of mismatch repair status, the implications of mismatch repair deficiency in cancer cells, and how elevated mutation rate associated with MSI-H tumor cells drive the production of neoantigens thought to contribute to immunotherapeutic response.

Learning Objectives:

• Recall implications of mismatch repair deficiency in solid tumors
• Define Key advantages of Long Mononucleotide Repeats (LMRs) in detecting microsatellite instability

SEE ABSTRACT HIDE ABSTRACT | Continuing Education: Florida CE | P.A.C.E. CE
Past, Present and Future: Advances in MSI Testing

Jeff Bacher, PhD

Senior Research Scientist, Promega Corporation, Adjunct Professor, UW-Madison, Dept. of Medicine
BIOGRAPHY

Dr. Bacher will be discussing the history and evolution of MSI, the differences between popular testing methods, and what the future holds for this powerful biomarker.

Learning Objectives:

• Explain what a microsatellite is, how errors in microsatellites are repaired and indicate how MSI testing is done
• Compare and contrast the characteristics of laboratory assays used to test for microsatellite instability in solid tumors

SEE ABSTRACT HIDE ABSTRACT | Continuing Education: Florida CE | P.A.C.E. CE

C.E. Credits

The speakers below have been approved for Continuing Education Credits. To redeem your credits, locate the presentation you watched and click on the CE buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here

Past, Present and Future: Advances in MSI Testing

Jeff Bacher, PhD

Senior Research Scientist, Promega Corporation, Adjunct Professor, UW-Madison, Dept. of Medicine

Presented at: A Microsatellite Instability (MSI) Series

P.A.C.E. CE

Florida CE
MSI Predicts Immunotherapeutic Response

James Eshleman, MD, PhD

Professor of Pathology and Oncology, Associate Director, Molecular Diagnostics Laboratory, Johns Hopkins University School of Medicine

Presented at: A Microsatellite Instability (MSI) Series

P.A.C.E. CE

Florida CE
Universal Tumor Screening for Lynch Syndrome: Past,...

Heather Hampel, MS

LGC Associate Director, Division of Human Genetics, Associate Director, Biospecimen Research Professor, Internal Medicine, Licensed Genetic Counselor, The Ohio State University Cancer Center

Presented at: A Microsatellite Instability (MSI) Series

P.A.C.E. CE

Florida CE
JUN 29, 2021 10:00 AM CDT

Colorectal Cancer Disparities and the Role of MSI Testing...

Dr. Ryan Nguyen, DO

Chief Hematology and Oncology Fellow, University of Illinois at Chicago

Presented at: A Microsatellite Instability (MSI) Series

P.A.C.E. CE

Florida CE
JUN 29, 2021 10:40 AM CDT

Development of a Microsatellite Instability Assay Utilizing...

Dr. Samantha Lewis, Ph.D.

Clinical Development Specialist, Promega Corporation

Presented at: A Microsatellite Instability (MSI) Series

P.A.C.E. CE

Florida CE
Oct 26, 2021 11:00 AM CDT

Current Gold-Standards for MSI Testing and the Clinical...

Dr. Emily Teslow, Ph.D.

Medical Science Liaison, Medical Affairs Dept, Promega Corporation

Presented at: A Microsatellite Instability (MSI) Series

P.A.C.E. CE

Florida CE

Help

General Labroots Questions

email support@labroots.com

Virtual Events and Webinars

Supported Configurations

Operating System	Internet Explorer	Firefox	Chrome	Safari
Vista	IE8+	FF10+	Chrome15+
Windows 7	IE8+	FF10+	Chrome15+
Windows 8	IE10	FF10+	Chrome15+
Mac OS X		FF10+	Chrome15+	Safari5.1+

Cookie settings: session cookies enabled
Browser configuration must have JavaScript enabled
Adobe Flash player 10.2 or later

To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

Internet Connection

A minimum of 100Kbps is recommended for audio-only events
A minimum of 300Kbps is recommended for speaker on-video events

Computer Equipment

Screen Resolution: Minimum 1024x768
Video Card: 65,000 colors minimum
Sound card and speakers (or headphones) for hearing webcast in full format
Audio Card: 16-bit minimum
RAM: 512MB of free RAM

Firewall Protocol

HTTP on port 80 or HTTPS on port 443
Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
RTMPE (RTMP encrypted) on ports 1935, 80 or 443

Work-At-Home Attendees

If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

For A Seamless Experience

Registration is required for most events
Adobe Flash Player is needed to view webinar videos
Self Test your system compatibility ahead of time

When using a mobile device, FREE Mobile Apps are available:

- For viewing Webinars:

iPhone/iPad, download the Webcast Studio App
Android device, download the Webcast Studio App

- For viewing Virtual Events

iPhone/iPad, download the Virtual Environments App
Android, download the Virtual Environments App

Attendee Guide

To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

Virtual Event and Webinar Support:

Email: support@labroots.com
Webpage: About Virtual Events

Continuing Education (CME/CE) Support

Phone: +1-714-930-3518
Email: CE@labroots.com
Webpage: Continuing Education CME/CE Credits

A Microsatellite Instability (MSI) Series

Kathryn Oostdik

Dr. Emily Teslow, Ph.D.

Dr. Ryan Nguyen, DO

Dr. Samantha Lewis, Ph.D.

Dr. Pamela Ward, Ph.D.

Jeff Bacher, PhD

James Eshleman, MD, PhD

Heather Hampel, MS

Gerard Blobe, MD, PhD